Liminal Biosciences Inc.’s stock

soared 91% in premarket trade Wednesday, after the company said it’s received an unsolicited takeover offer of $7.50 a share from Structured Alpha LP. That company already owns 64% of the outstanding stock and is now bidding for the rest. The stock closed Tuesday at $3.62. Liminal specializes in discovering and developing novel and distinctive small molecule therapeutics to treat metabolic, inflammatory and fibrotic diseases. The board will review the offer and has formed a special committee of independent directors.

Source link

Leave a comment

Your email address will not be published. Required fields are marked *